HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TRANSTHERA-B

9.375

-0.085-0.90%

Volume:3.50M

Turnover:32.33M

Market Cap:3.82B

PE:-10.55

High:9.490

Open:9.425

Low:9.010

Close:9.460

52wk High:679.500

52wk Low:9.010

Shares:407.00M

HK Float Shares:312.00M

Volume Ratio:0.92

T/O Rate:1.12%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.888

ROE:-36.78%

ROA:-20.32%

PB:3.72

PE(LYR):-10.55

PS:92.07

Loading ...

Overview Company News Filings

TransThera doses first patient in China Phase III tinengotinib trial for advanced cholangiocarcinoma

TRANSTHERA-B Announces Private Placement of 5.085 Million Shares at 18% Discount

TransThera Sciences announces HK$290.00 million H-share placement; 5.09 million new shares priced at 18% discount

Bulletin Express

TransThera Sciences to place 5,085,000 new H shares at HK$57.03 each

Transthera Sciences (Nanjing) Inc - Placing of 5.1 Mln Shares at HK$57.03 per Share

THOMSON REUTERS

TRANSTHERA-B Proposes Implementation of H-Share Incentive Scheme

TRANSTHERA-B Board Endorses 2026 H-Share Award Scheme, Seeks Shareholder and HKEX Nod

Bulletin Express

TransThera proposes H-share award scheme for employee compensation

TransThera Sciences files directors list with Hong Kong Stock Exchange

TransThera Sciences names Feng Weibo independent director, replacing Zheng Zhelan

TransThera proposes bylaw amendments shifting supervisory powers to board audit committee

Transthera FY25 net loss widens 8% to RMB 296 million

TransThera Sciences: INED Zheng Zhelan to Exit, Feng Weibo Nominated as Successor; Non-Executive Director Yi Hua Resigns

Bulletin Express

TRANSTHERA-B Proposes Appointment of Feng Weibo as Independent Non-Executive Director

TransThera Sciences Widens Loss in 2025

MT Newswires Live

TRANSTHERA-B Reports 2025 Fiscal Year Results: Net Loss Widens to 296 Million Yuan

BRIEF-Transthera Sciences (Nanjing) FY Loss Attributable Rmb296 Million

Transthera Sciences (Nanjing) Inc - FY Loss Attributable RMB296 Mln

THOMSON REUTERS

TRANSTHERA-B (02617) Sets 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend

Bulletin Express

TransThera Sciences to hold board meeting on annual results and final dividend

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/02617/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":9.375,"timestamp":1789114135007,"preClose":9.46,"halted":0,"volume":3498500,"delay":0,"changeRate":-0.008985200845666052,"floatShares":312000000,"shares":407000000,"eps":-0.8883672637159259,"marketStatus":"Closed","change":-0.085,"latestTime":"09-11 16:08:55","open":9.425,"high":9.49,"low":9.01,"amount":32325872,"amplitude":0.05074,"askPrice":9.38,"askSize":500,"bidPrice":9.375,"bidSize":709000,"shortable":3,"etf":0,"ttmEps":-0.7861746368769409,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":5,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":9.46,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":0.919956,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":312000000,"roa":"-20.32%","roe":"-36.78%","lyrEps":-0.888378,"volumeRatio":0.919956,"shares":407000000,"dividePrice":0,"high":9.49,"amplitude":0.05074,"preClose":9.46,"low":9.01,"week52Low":9.01,"pbRate":"3.72","psRate":"92.07","week52High":679.5,"institutionHeld":0,"latestPrice":9.375,"committee":0.998591,"eps":-0.8883781770273768,"divideRate":0,"volume":3498500,"delay":0,"ttmEps":-0.7861842947842249,"open":9.425,"prevYearClose":114.9,"prevWeekClose":10.15,"prevMonthClose":10.17,"prevQuarterClose":11.55,"fiveDayClose":10.15,"twentyDayClose":10.33,"sixtyDayClose":28.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"market":"HK","date":"2026-03-31","symbol":"02617","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774886400000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2026-09-10","current":-11.924831,"percent":0.92691,"low":-380.446233,"twenty":-195.578699,"median":-71.771981,"eighty":-33.305971,"high":-10.87103,"avg":-110.030434,"sd":96.347657,"marketCap":3858910268},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642},{"date":"2025-09-12","current":-176.221101,"twenty":-67.557018,"median":-51.642061,"eighty":-40.181616,"marketCap":76402794352},{"date":"2025-09-19","current":-137.321051,"twenty":-71.134174,"median":-54.042597,"eighty":-40.68225,"marketCap":59494955186},{"date":"2025-09-26","current":-219.814439,"twenty":-72.736767,"median":-55.62397,"eighty":-41.23574,"marketCap":56835741045},{"date":"2025-10-03","current":-208.418403,"twenty":-113.88308,"median":-57.213624,"eighty":-41.375772,"marketCap":54017767851},{"date":"2025-10-10","current":-183.264838,"twenty":-172.633767,"median":-57.790453,"eighty":-41.583173,"marketCap":47429267143},{"date":"2025-10-17","current":-311.562728,"twenty":-178.967921,"median":-58.015216,"eighty":-41.927636,"marketCap":80570219499},{"date":"2025-10-24","current":-293.038662,"twenty":-206.454369,"median":-63.574223,"eighty":-42.029097,"marketCap":75807447903},{"date":"2025-10-31","current":-281.572204,"twenty":-212.338922,"median":-65.741367,"eighty":-42.067733,"marketCap":72949784945},{"date":"2025-11-07","current":-338.772318,"twenty":-240.199465,"median":-68.232426,"eighty":-42.195906,"marketCap":87714376893},{"date":"2025-11-14","current":-312.135011,"twenty":-262.893893,"median":-70.289151,"eighty":-42.482614,"marketCap":81046496658},{"date":"2025-11-21","current":-312.892206,"twenty":-281.392507,"median":-71.392356,"eighty":-43.133487,"marketCap":81205255711},{"date":"2025-11-28","current":-305.66478,"twenty":-292.6573,"median":-72.756691,"eighty":-44.126885,"marketCap":79617665179},{"date":"2025-12-05","current":-292.058382,"twenty":-294.387608,"median":-99.507708,"eighty":-45.187328,"marketCap":76204345536},{"date":"2025-12-12","current":-243.995471,"twenty":-293.167092,"median":-152.573856,"eighty":-47.193393,"marketCap":63781449623},{"date":"2025-12-19","current":-248.269013,"twenty":-292.997062,"median":-174.177612,"eighty":-49.176233,"marketCap":65051522048},{"date":"2025-12-24","current":-196.609225,"twenty":-292.87226,"median":-176.029803,"eighty":-49.50215,"marketCap":51676071816},{"date":"2026-01-02","current":-170.268162,"twenty":-292.367293,"median":-176.029803,"eighty":-50.024601,"marketCap":44928812055},{"date":"2026-01-09","current":-172.395935,"twenty":-291.502465,"median":-173.687618,"eighty":-50.606284,"marketCap":45603538031},{"date":"2026-01-16","current":-142.824051,"twenty":-290.689477,"median":-172.622298,"eighty":-50.90198,"marketCap":37903723951},{"date":"2026-01-23","current":-125.658859,"twenty":-289.035292,"median":-170.268162,"eighty":-51.777834,"marketCap":33316302355},{"date":"2026-01-30","current":-123.813683,"twenty":-286.862177,"median":-169.566856,"eighty":-52.840115,"marketCap":32977154367},{"date":"2026-02-06","current":-105.494623,"twenty":-283.350344,"median":-167.82666,"eighty":-53.700055,"marketCap":28169232889},{"date":"2026-02-13","current":-102.143547,"twenty":-281.033113,"median":-142.637109,"eighty":-54.549461,"marketCap":27431087268},{"date":"2026-02-20","current":-99.091969,"twenty":-280.673719,"median":-140.820404,"eighty":-54.88737,"marketCap":26573242357},{"date":"2026-02-27","current":-101.401985,"twenty":-277.873293,"median":-135.446139,"eighty":-55.077905,"marketCap":27490936913},{"date":"2026-03-06","current":-136.499284,"twenty":-268.489172,"median":-127.818396,"eighty":-56.170035,"marketCap":36707782236},{"date":"2026-03-13","current":-113.20329,"twenty":-265.946326,"median":-125.658859,"eighty":-56.966285,"marketCap":30583168569},{"date":"2026-03-20","current":-101.699451,"twenty":-264.885138,"median":-122.419285,"eighty":-57.460964,"marketCap":27371237623},{"date":"2026-03-27","current":-103.891016,"twenty":-259.5894,"median":-118.720319,"eighty":-57.713018,"marketCap":27889934546},{"date":"2026-04-02","current":-103.689961,"twenty":-256.279611,"median":-116.735022,"eighty":-57.836913,"marketCap":27969734073},{"date":"2026-04-10","current":-80.663784,"twenty":-255.242863,"median":-113.754326,"eighty":-57.879207,"marketCap":27371237623},{"date":"2026-04-17","current":-81.335146,"twenty":-254.749157,"median":-113.20329,"eighty":-57.943799,"marketCap":27610636203},{"date":"2026-04-24","current":-69.75013,"twenty":-253.791099,"median":-110.250158,"eighty":-58.025793,"marketCap":23679242293},{"date":"2026-04-30","current":-61.379887,"twenty":-252.626844,"median":-107.193308,"eighty":-58.709304,"marketCap":20850663862},{"date":"2026-05-08","current":-65.459145,"twenty":-251.564027,"median":-106.48355,"eighty":-58.020504,"marketCap":22305361341},{"date":"2026-05-15","current":-57.457667,"twenty":-249.188687,"median":-106.083059,"eighty":-57.919993,"marketCap":19630334311},{"date":"2026-05-22","current":-50.784784,"twenty":-247.674355,"median":-104.198267,"eighty":-57.649604,"marketCap":17310899997},{"date":"2026-05-29","current":-41.763424,"twenty":-245.295721,"median":-103.852131,"eighty":-57.457667,"marketCap":14285310527},{"date":"2026-06-05","current":-37.606441,"twenty":-243.995471,"median":-103.234551,"eighty":-55.321243,"marketCap":12882070430},{"date":"2026-06-12","current":-38.299212,"twenty":-239.592317,"median":-102.28828,"eighty":-53.347698,"marketCap":13110504864},{"date":"2026-06-18","current":-33.64261,"twenty":-235.649979,"median":-102.143547,"eighty":-51.161877,"marketCap":11544097313},{"date":"2026-06-26","current":-10.87103,"twenty":-223.802745,"median":-101.125662,"eighty":-50.162538,"marketCap":3712059560},{"date":"2026-07-03","current":-14.085963,"twenty":-220.323597,"median":-100.505297,"eighty":-47.51031,"marketCap":4813439869},{"date":"2026-07-10","current":-12.489761,"twenty":-217.694001,"median":-99.314488,"eighty":-43.652943,"marketCap":4262749714},{"date":"2026-07-17","current":-11.456979,"twenty":-215.893769,"median":-98.774546,"eighty":-42.55123,"marketCap":3924177249},{"date":"2026-07-24","current":-12.133097,"twenty":-213.808047,"median":-93.131819,"eighty":-41.957553,"marketCap":4156690870},{"date":"2026-07-31","current":-11.824868,"twenty":-212.088453,"median":-87.290837,"eighty":-41.541423,"marketCap":4058790398},{"date":"2026-08-07","current":-13.332054,"twenty":-210.416628,"median":-83.155604,"eighty":-40.356892,"marketCap":4585005434},{"date":"2026-08-14","current":-12.237188,"twenty":-208.788963,"median":-82.408413,"eighty":-39.630155,"marketCap":4213799478},{"date":"2026-08-21","current":-12.186563,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"marketCap":4205641106},{"date":"2026-08-28","current":-13.544101,"twenty":-206.454369,"median":-79.928564,"eighty":-37.623415,"marketCap":4242353783},{"date":"2026-09-04","current":-13.213217,"twenty":-200.748681,"median":-72.756691,"eighty":-35.040401,"marketCap":4140374124},{"date":"2026-09-10","current":-12.298382,"twenty":-195.578699,"median":-71.771981,"eighty":-33.305971,"marketCap":3858910268}],"updateTime":1789126004676},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2628270114","title":"TransThera doses first patient in China Phase III tinengotinib trial for advanced cholangiocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2628270114","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628270114?lang=en_us&edition=fundamental","pubTime":"2026-04-17 18:40","pubTimestamp":1776422454,"startTime":"0","endTime":"0","summary":"TransThera dosed first patient in China confirmatory Phase III trial of tinengotinib monotherapy for advanced intrahepatic cholangiocarcinoma with FGFR2 alterations.Study will compare tinengotinib versus chemotherapy in patients whose disease relapsed or progressed following first-line systemic therapy.No clinical results were presented; efficacy and safety readout will be generated in future as trial progresses.Program supports marketing push in China, with tinengotinib already at NDA review stage following completion of pivotal Phase II study.Company positioned drug as potential option for patients previously treated with FGFR inhibitors, targeting unmet need tied to treatment resistance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL57VbVH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121459065","title":"TRANSTHERA-B Announces Private Placement of 5.085 Million Shares at 18% Discount","url":"https://stock-news.laohu8.com/highlight/detail?id=1121459065","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121459065?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:06","pubTimestamp":1776207983,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) has entered into a placement agreement with a placement agent. The agreement, dated April 14, 2026, stipulates that the agent will use its best efforts to place 5.085 million...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178263361","title":"TransThera Sciences announces HK$290.00 million H-share placement; 5.09 million new shares priced at 18% discount","url":"https://stock-news.laohu8.com/highlight/detail?id=1178263361","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178263361?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:43","pubTimestamp":1776206599,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (abbreviated “TransThera Sciences”) on 14 April 2026 signed a conditional placing agreement with Macquarie Capital Limited to issue 5.09 million new H shares at...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627291427","title":"TransThera Sciences to place 5,085,000 new H shares at HK$57.03 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2627291427","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627291427?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:32","pubTimestamp":1776205929,"startTime":"0","endTime":"0","summary":"TransThera Sciences entered a placing agreement to sell 5,085,000 new H shares at HK$ 57.03 each.Deal size implies gross proceeds of about HK$ 290 million.Pricing represents an 18% discount to April 14 close of HK$ 69.55.Net proceeds expected at about HK$ 282.2 million.Funds earmarked mainly for R&D and Tinengotinib manufacturing and commercialization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 14, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL3kD9vl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627542725","title":"Transthera Sciences (Nanjing) Inc -  Placing of 5.1 Mln Shares at HK$57.03 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2627542725","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627542725?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:31","pubTimestamp":1776205891,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40X16U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190520691","title":"TRANSTHERA-B Proposes Implementation of H-Share Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1190520691","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190520691?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:44","pubTimestamp":1775565852,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) has announced that its board of directors passed a resolution during a meeting held on April 7, 2026, recommending the adoption of an H-share incentive plan. The awards under the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148728314","title":"TRANSTHERA-B Board Endorses 2026 H-Share Award Scheme, Seeks Shareholder and HKEX Nod","url":"https://stock-news.laohu8.com/highlight/detail?id=1148728314","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148728314?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:45","pubTimestamp":1775562327,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (TRANSTHERA-B) has approved a proposal to establish a 2026 H Share Award Scheme aimed at incentivising employees, related-party participants and service providers....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625937130","title":"TransThera proposes H-share award scheme for employee compensation","url":"https://stock-news.laohu8.com/highlight/detail?id=2625937130","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625937130?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:40","pubTimestamp":1775562013,"startTime":"0","endTime":"0","summary":"Transthera Sciences board on April 7, 2026 proposed adoption of a 2026 H share award scheme.Awards would be settled using treasury shares, newly issued H shares, or existing H shares.Plan defines awards as share options or share awards granted to eligible participants.Company plans to call an extraordinary general meeting to seek shareholder backing for scheme adoption.Scheme would also require listing approval for shares to be issued under awards.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 07, 2026, and is solely responsible for the information contai","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDLcgT3vd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624593585","title":"TransThera Sciences files directors list with Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2624593585","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624593585?lang=en_us&edition=fundamental","pubTime":"2026-04-01 06:26","pubTimestamp":1774995960,"startTime":"0","endTime":"0","summary":"Transthera Sciences  filed list of directors and board committee roles with Hong Kong Stock Exchange dated March 31, 2026.Board includes two executive directors: Frank Wu, Wu Di.Independent non-executive directors include Chui Hoi Yam, Zheng Zhelan, Li Shu Pai.Committee leadership includes Li Shu Pai chairing Audit Committee, Zheng Zhelan chairing Remuneration and Appraisal Committee, Chui Hoi Yam chairing Nomination Committee, Frank Wu chairing Strategy Committee.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 31, 2026, and is solely responsible for the i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLFz9hZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","600962","BK0081","BK0102","BK0082","BK0215","02617","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624555183","title":"TransThera Sciences names Feng Weibo independent director, replacing Zheng Zhelan","url":"https://stock-news.laohu8.com/highlight/detail?id=2624555183","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624555183?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:41","pubTimestamp":1774993298,"startTime":"0","endTime":"0","summary":"TransThera Sciences  disclosed planned board reshuffle dated March 31, 2026, with independent director Zheng Zhelan set to step down once successor is elected at next annual general meeting.Board nominated Feng Weibo as independent non-executive director for a three-year term starting on shareholder approval.Feng is a retired Nanjing University education management researcher, previously serving in teaching and party secretary roles, currently independent director at Shenzhen-listed Nanjing Toua Hardware & Tools.Feng is slated to take over as chair of remuneration and appraisal committee, with seats on audit committee and nomination committee.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the origin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL3PNgJ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1095","02617","09898","BK1615","301125","BK1161","BK0259"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624555374","title":"TransThera proposes bylaw amendments shifting supervisory powers to board audit committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2624555374","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624555374?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:31","pubTimestamp":1774992702,"startTime":"0","endTime":"0","summary":"TransThera Sciences proposed bylaw amendments to align governance documents with China’s revised Company Law.Plan dissolves supervisory committee, shifting its oversight duties to board audit committee.Shareholders will vote on amended articles of association via special resolution at upcoming annual general meeting.Revisions to rules for shareholders’ meetings, board procedures face ordinary-resolution votes at same meeting.Supervisory committee members will step down once amended articles take effect.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 31, 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLt4jdX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624558124","title":"Transthera FY25 net loss widens 8% to RMB 296 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624558124","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624558124?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:57","pubTimestamp":1774990665,"startTime":"0","endTime":"0","summary":"Transthera Sciences posted a net loss of RMB 296 million for fiscal 2025, with loss per share of RMB 0.76.Revenue was unchanged at no revenue, while loss before tax widened to RMB 296 million.Other income and gains fell 48.6% to RMB 9.2 million, due to lower interest income and reduced government grants.Tinengotinib’s new drug application for cholangiocarcinoma was accepted by China’s NMPA on Dec. 19, 2025, with a confirmatory Phase III trial ongoing in China and a registrational multi-regional Phase III trial underway overseas.Management expects Tinengotinib to secure NDA approval in China in 2026, while continuing Phase II combination trials in prostate cancer, breast cancer, and hepatocellular carcinoma.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL4jb95x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107897077","title":"TransThera Sciences: INED Zheng Zhelan to Exit, Feng Weibo Nominated as Successor; Non-Executive Director Yi Hua Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=1107897077","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107897077?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:05","pubTimestamp":1774958722,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing), Inc. (TransThera) announced a forthcoming reshuffle of its board on 31 March 2026, involving both independent and non-executive directors. Resignation of Independent...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163942223","title":"TRANSTHERA-B Proposes Appointment of Feng Weibo as Independent Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1163942223","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163942223?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:58","pubTimestamp":1774958330,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that its board of directors received a resignation letter dated March 31, 2026, from the company's independent non-executive director, Ms. Zheng Zhelan. Due to personal...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623435585","title":"TransThera Sciences Widens Loss in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2623435585","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623435585?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:26","pubTimestamp":1774956404,"startTime":"0","endTime":"0","summary":"TransThera Sciences  widened its attributable loss in 2025 to 296 million yuan from 274.6 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.The clinical-stage biopharmaceutical firm's loss per share stood at 0.76 yuan in the fiscal year, compared with 0.72 yuan in the previous corresponding year.The firm did not record any revenue in both periods.Other income and gains fell 49% to 9.2 million yuan from 17.9 million yuan in the year-ago period, mainly due to a decline in interest income from bank deposits and wealth management products and lower government grants.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119552767","title":"TRANSTHERA-B Reports 2025 Fiscal Year Results: Net Loss Widens to 296 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1119552767","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119552767?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:50","pubTimestamp":1774954223,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced its annual results for the period ending December 31, 2025. Other income and gains fell by 48.6% year-on-year to 9.2 million yuan (Renminbi) for the 2025 fiscal year....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623289588","title":"BRIEF-Transthera Sciences (Nanjing) FY Loss Attributable Rmb296 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623289588","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623289588?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:45","pubTimestamp":1774953936,"startTime":"0","endTime":"0","summary":"BRIEF-Transthera Sciences (Nanjing) FY Loss Attributable Rmb296 MillionMarch 31 (Reuters) - TransThera Sciences (Nanjing) Inc 2617.HK:FY LOSS ATTRIBUTABLE RMB296 MILLIONFurther company coverage: 2617.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J0JD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623058819","title":"Transthera Sciences (Nanjing) Inc - FY Loss Attributable RMB296 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623058819","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623058819?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:42","pubTimestamp":1774953731,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J0JD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181323580","title":"TRANSTHERA-B (02617) Sets 31 Mar 2026 Board Meeting to Approve FY2025 Results and Consider Final Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1181323580","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181323580?lang=en_us&edition=fundamental","pubTime":"2026-03-19 18:22","pubTimestamp":1773915740,"startTime":"0","endTime":"0","summary":"On 19 March 2026, TransThera Sciences (Nanjing), Inc. (stock code: 02617, “TRANSTHERA-B”) announced that its board of directors will convene on 31 March 2026. The agenda includes: • Reviewing and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620246749","title":"TransThera Sciences to hold board meeting on annual results and final dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2620246749","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620246749?lang=en_us&edition=fundamental","pubTime":"2026-03-19 18:10","pubTimestamp":1773915047,"startTime":"0","endTime":"0","summary":"TransThera will hold a board meeting on 31 March 2026 to consider and approve its annual results announcement and to consider a final dividend.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 19, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL6dhhWb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":7,"totalSize":147,"code":"91000000","status":"200"}]}}